PriceTargets.com logo

Zafgen - ZFGN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.38 As of 04/18/2024 01:00 AM ET
▼ -0.67 (-9.50%)
Get New Zafgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZFGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZFGN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Zafgen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.38.

This chart shows the closing price for ZFGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Zafgen. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/23/2019WedbushReiterated RatingHold$0.78N/A
11/14/2019WedbushReiterated RatingHold$0.78Low
9/6/2019Roth CapitalDowngradeBuy ➝ NeutralLow
9/6/2019WedbushDowngradeOutperform ➝ Neutral$6.00 ➝ $0.78High
9/5/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/12/2019WedbushReiterated RatingOutperform$6.00Medium
5/30/2019WedbushReiterated RatingBuy$6.00Medium
5/30/2019CowenReiterated RatingHoldMedium
5/30/2019Piper Sandler CompaniesLower TargetOverweight ➝ Hold$6.00 ➝ $5.00Medium
5/16/2019WedbushReiterated RatingBuy$6.00Medium
4/26/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Zafgen logo
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.38
Low: $6.33
High: $7.00

50 Day Range

MA: $18.47
Low: $0.99
High: $25.06

52 Week Range

Now: $6.38
Low: $0.62
High: $2.76

Volume

510,792 shs

Average Volume

360,199 shs

Market Capitalization

$239.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Zafgen?

The following Wall Street research analysts have issued stock ratings on Zafgen in the last twelve months:
View the latest analyst ratings for ZFGN.

What is the current price target for Zafgen?

0 Wall Street analysts have set twelve-month price targets for Zafgen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zafgen in the next year.
View the latest price targets for ZFGN.

What is the current consensus analyst rating for Zafgen?

Zafgen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZFGN.

What other companies compete with Zafgen?

Other companies that are similar to Zafgen include Pyxis Oncology, XBiotech, Prelude Therapeutics, Nektar Therapeutics and Verastem. Learn More about companies similar to Zafgen.

How do I contact Zafgen's investor relations team?

Zafgen's physical mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company's listed phone number is 617-622-4003 and its investor relations email address is [email protected]. The official website for Zafgen is www.zafgen.com. Learn More about contacing Zafgen investor relations.